ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

ClinicalTrials.gov ID: NCT03945162

Public ClinicalTrials.gov record NCT03945162. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Clinical Study of Intravesical Ruvidar® in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") or Patients Who Are Intolerant to BCG Therapy ("Study II")

Study identification

NCT ID
NCT03945162
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Theralase® Technologies Inc.
Industry
Enrollment
90 participants

Conditions and interventions

Interventions

  • Ruvidar® (TLD-1433) bladder infusion and PDT Combination Product

Combination Product

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 29, 2019
Primary completion
Nov 30, 2026
Completion
Nov 30, 2027
Last update posted
Nov 23, 2025

2019 – 2027

United States locations

U.S. sites
10
U.S. states
10
U.S. cities
10
Facility City State ZIP Site status
Site 02-012 - University of Chicago Chicago Illinois 60637 Recruiting
Site 02-016 - Urology of Indiana Greenwood Indiana 46143 Recruiting
Site 02-015 - Associated Medical Professionals of New York Syracuse New York 13210 Recruiting
Site 02-017 - Central Ohio Urology Group Gahanna Ohio 43230 Recruiting
Site 02-008 - MidLantic Urology Bala-Cynwyd Pennsylvania 19004 Terminated
Site 02-006 - Carolina Urologic Research Center Myrtle Beach South Carolina 29572 Recruiting
Site 02-007 - Urology Associates, P. C Nashville Tennessee 37209 Recruiting
Site 02-010 - Urology San Antonio P. A San Antonio Texas 78229 Terminated
Site 02-009 - Virginia Urology Richmond Virginia 23235 Terminated
Site 02-011 - University of Wisconsin Health University Hospital Madison Wisconsin 53792 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03945162, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 23, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03945162 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →